180 related articles for article (PubMed ID: 38482842)
1. Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease.
Miller M
Curr Opin Cardiol; 2024 Jul; 39(4):286-291. PubMed ID: 38482842
[TBL] [Abstract][Full Text] [Related]
2. Fibrates, Hypertriglyceridemia, and CVD Risk: Where Do We Stand After the PROMINENT Trial for Triglyceride Lowering?
Chukwurah MI; Miller M
Curr Cardiol Rep; 2023 Sep; 25(9):987-992. PubMed ID: 37505399
[TBL] [Abstract][Full Text] [Related]
3. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
4. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
[TBL] [Abstract][Full Text] [Related]
5. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
6. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
7. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
8. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
[TBL] [Abstract][Full Text] [Related]
9. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.
Picard F; Steg PG
Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki KC; Dicklin MR
Curr Opin Cardiol; 2020 Jul; 35(4):417-422. PubMed ID: 32412960
[TBL] [Abstract][Full Text] [Related]
12. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
[TBL] [Abstract][Full Text] [Related]
13. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes.
Alexopoulos AS; Qamar A; Hutchins K; Crowley MJ; Batch BC; Guyton JR
Curr Diab Rep; 2019 Feb; 19(4):13. PubMed ID: 30806837
[TBL] [Abstract][Full Text] [Related]
14. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
[TBL] [Abstract][Full Text] [Related]
15. Triglycerides and residual risk.
Vallejo-Vaz AJ; Corral P; Schreier L; Ray KK
Curr Opin Endocrinol Diabetes Obes; 2020 Apr; 27(2):95-103. PubMed ID: 32073428
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
[TBL] [Abstract][Full Text] [Related]
17. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
Mosca L; Navar AM; Wenger NK
J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
Pradhan AD; Paynter NP; Everett BM; Glynn RJ; Amarenco P; Elam M; Ginsberg H; Hiatt WR; Ishibashi S; Koenig W; Nordestgaard BG; Fruchart JC; Libby P; Ridker PM
Am Heart J; 2018 Dec; 206():80-93. PubMed ID: 30342298
[TBL] [Abstract][Full Text] [Related]
19. Investigational drugs in development for hypertriglyceridemia: a coming-of-age story.
Rhainds D; Brodeur MR; Tardif JC
Expert Opin Investig Drugs; 2019 Dec; 28(12):1059-1079. PubMed ID: 31752565
[No Abstract] [Full Text] [Related]
20. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]